A randomized, controlled trial of baroreflex activation therapy (BAT) in patients with heart failure and reduced ejection fraction demonstrated that BAT was safe significantly improved patient-centered symptomatic outcomes, increasing exercise capacity, improving quality life , decreasing n-terminal pro B-type natriuretic peptide (NT-proBNP), functional class. approved by the FDA for improvemen...